Skip to main content
Top
Published in: Journal of Clinical Immunology 1/2020

01-01-2020 | Vasculitis | Original Article

STING-Associated Vasculopathy with Onset in Infancy in Three Children with New Clinical Aspect and Unsatisfactory Therapeutic Responses to Tofacitinib

Authors: Xiaolei Tang, Hui Xu, Chunju Zhou, Yun Peng, Hui Liu, Jinrong Liu, Huimin Li, Haiming Yang, Shunying Zhao

Published in: Journal of Clinical Immunology | Issue 1/2020

Login to get access

Abstract

Purpose

STING-associated vasculopathy with onset in infancy (SAVI) is a new rare auto-inflammatory disease. The purpose of this study is to report new cases and summarize the manifestations and outcome of SAVI.

Methods

We made a retrospective analysis of three pediatric patients diagnosed with SAVI between March 2016 and July 2018 in Beijing Children’s Hospital.

Results

Three patients comprised one boy and two girls. The median age of onset was 4 months. All patients had the same de novo heterozygous mutation (c.463G>A, p. V155M) of TMEM173. All patients presented with interstitial lung disease and one coexisted with diffuse alveolar hemorrhage. Rashes were presented in two patients. Other clinical manifestations include febrile attacks, failure to thrive, arthritis, myositis, cerebrovascular involvement, ureteral calculus, gastroesophageal reflux, and malnutrition. Ground-glass opacities were the most common features of chest computed tomography, followed with cysts and reticular opacities. Transbronchial lung biopsy was performed in one patient revealing pulmonary vasculitis. Skin biopsy was performed in one patient with changes of vasculitis. All patients were treated with corticosteroids and two patients received combined treatment of tofacitinib. The therapeutic effects of tofacitinib were limited on interstitial lung disease in both patients and were poor on rashes in one patient. One patient under the treatment of tofacitinib died.

Conclusions

New clinical aspect of diffuse alveolar hemorrhage is first reported to be associated with SAVI. Unsatisfactory therapeutic effects of tofacitinib are observed in this study and further evaluations are needed.
Literature
1.
go back to reference Liu Y, Jesus AA, Marrero B, Yang D, Ramsey SE, Montealegre Sanchez GA, et al. Activated STING in a vascular and pulmonary syndrome. N Engl J Med. 2014;371(6):507–18.CrossRef Liu Y, Jesus AA, Marrero B, Yang D, Ramsey SE, Montealegre Sanchez GA, et al. Activated STING in a vascular and pulmonary syndrome. N Engl J Med. 2014;371(6):507–18.CrossRef
2.
go back to reference Picard C, Mathieu A-L, Hasan U, Henry T, Jamilloux Y, Walzer T, et al. Inherited anomalies of innate immune receptors in pediatric-onset inflammatory diseases. Autoimmun Rev. 2015;14(12):1147–53.CrossRef Picard C, Mathieu A-L, Hasan U, Henry T, Jamilloux Y, Walzer T, et al. Inherited anomalies of innate immune receptors in pediatric-onset inflammatory diseases. Autoimmun Rev. 2015;14(12):1147–53.CrossRef
3.
go back to reference Jeremiah N, Neven B, Gentili M, Callebaut I, Maschalidi S, Stolzenberg MC, et al. Inherited STING-activating mutation underlies a familial inflammatory syndrome with lupus-like manifestations. J Clin Invest. 2014;124(12):5516–20.CrossRef Jeremiah N, Neven B, Gentili M, Callebaut I, Maschalidi S, Stolzenberg MC, et al. Inherited STING-activating mutation underlies a familial inflammatory syndrome with lupus-like manifestations. J Clin Invest. 2014;124(12):5516–20.CrossRef
4.
go back to reference Picard C, Thouvenin G, Kannengiesser C, Dubus JC, Jeremiah N, Rieux-Laucat F, et al. Severe pulmonary fibrosis as the first manifestation of interferonopathy (TMEM173 mutation). Chest. 2016;150(3):e65–71.CrossRef Picard C, Thouvenin G, Kannengiesser C, Dubus JC, Jeremiah N, Rieux-Laucat F, et al. Severe pulmonary fibrosis as the first manifestation of interferonopathy (TMEM173 mutation). Chest. 2016;150(3):e65–71.CrossRef
5.
go back to reference Yu Z, Zhong L, Song H, et al. Stimulator of interferon genes-associated vasculopathy with onset in infancy: first case report in China. Chin J Pediatr. 2018;56(3):179–85. Yu Z, Zhong L, Song H, et al. Stimulator of interferon genes-associated vasculopathy with onset in infancy: first case report in China. Chin J Pediatr. 2018;56(3):179–85.
6.
go back to reference Shoman W, El Chazli Y, ElSawy I, et al. First Egyptian patient with STING-associated vasculopathy with onset in infancy. Scand J Rheumatol. 2019;22:1–2. Shoman W, El Chazli Y, ElSawy I, et al. First Egyptian patient with STING-associated vasculopathy with onset in infancy. Scand J Rheumatol. 2019;22:1–2.
7.
go back to reference Omoyinmi E, Melo Gomes S, Nanthapisal S, Woo P, Standing A, Eleftheriou D, et al. Stimulator of interferon genes-associated vasculitis of infancy. Arthritis Rheum. 2015;67(3):808.CrossRef Omoyinmi E, Melo Gomes S, Nanthapisal S, Woo P, Standing A, Eleftheriou D, et al. Stimulator of interferon genes-associated vasculitis of infancy. Arthritis Rheum. 2015;67(3):808.CrossRef
8.
go back to reference Melki I, Rose Y, Uggenti C, van Eyck L, Frémond ML, Kitabayashi N, et al. Disease-associated mutations identify a novel region in human STING necessary for the control of type I interferon signaling. J Allergy Clin Immunol. 2017;140(2):543–52.CrossRef Melki I, Rose Y, Uggenti C, van Eyck L, Frémond ML, Kitabayashi N, et al. Disease-associated mutations identify a novel region in human STING necessary for the control of type I interferon signaling. J Allergy Clin Immunol. 2017;140(2):543–52.CrossRef
9.
go back to reference Munoz J, Rodière M, Jeremiah N, Rieux-Laucat F, Oojageer A, Rice GI, et al. Stimulator of interferon genes–associated vasculopathy with onset in infancy a mimic of childhood granulomatosis with polyangiitis. JAMA Dermatol. 2015;151(8):872–7.CrossRef Munoz J, Rodière M, Jeremiah N, Rieux-Laucat F, Oojageer A, Rice GI, et al. Stimulator of interferon genes–associated vasculopathy with onset in infancy a mimic of childhood granulomatosis with polyangiitis. JAMA Dermatol. 2015;151(8):872–7.CrossRef
10.
go back to reference Chia J, Eroglu FK, Özen S, Orhan D, Montealegre-Sanchez G, de Jesus AA, et al. Failure to thrive, interstitial lung disease, and progressive digital necrosis with onset in infancy. J Am Acad Dermatol. 2016 Jan;74(1):186–9.CrossRef Chia J, Eroglu FK, Özen S, Orhan D, Montealegre-Sanchez G, de Jesus AA, et al. Failure to thrive, interstitial lung disease, and progressive digital necrosis with onset in infancy. J Am Acad Dermatol. 2016 Jan;74(1):186–9.CrossRef
11.
go back to reference Sanchez GAM, Reinhardt A, Ramsey S. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J Clin Invest. 2018;128(7):3041–52.CrossRef Sanchez GAM, Reinhardt A, Ramsey S. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J Clin Invest. 2018;128(7):3041–52.CrossRef
12.
go back to reference Clarke SL, Pellowe EJ, de Jesus AA, et al. Interstitial lung disease caused by STING-associated vasculopathy with onset in infancy. Am J Respir Crit Care Med. 2016 Sep 1;194(5):639–42.CrossRef Clarke SL, Pellowe EJ, de Jesus AA, et al. Interstitial lung disease caused by STING-associated vasculopathy with onset in infancy. Am J Respir Crit Care Med. 2016 Sep 1;194(5):639–42.CrossRef
13.
go back to reference Seo J, Kang JA, Suh DI, Park EB, Lee CR, Choi SA, et al. Tofacitinib relieves symptoms of stimulator of interferon genes (STING)–associated vasculopathy with onset in infancy caused by 2 de novo variants in TMEM173. J Allergy Clin Immunol. 2017;139(4):1396–9.CrossRef Seo J, Kang JA, Suh DI, Park EB, Lee CR, Choi SA, et al. Tofacitinib relieves symptoms of stimulator of interferon genes (STING)–associated vasculopathy with onset in infancy caused by 2 de novo variants in TMEM173. J Allergy Clin Immunol. 2017;139(4):1396–9.CrossRef
14.
go back to reference König N, Fiehn C, Wolf C, Schuster M, Cura Costa E, Tüngler V, et al. Familial chilblain lupus due to a gain-of-function mutation in STING. Ann Rheum Dis. 2017 Feb;76(2):468–72.CrossRef König N, Fiehn C, Wolf C, Schuster M, Cura Costa E, Tüngler V, et al. Familial chilblain lupus due to a gain-of-function mutation in STING. Ann Rheum Dis. 2017 Feb;76(2):468–72.CrossRef
15.
go back to reference Manoussakis MN, Mavragani CP, Nezos A, Zampeli E, Germenis A, Moutsopoulos HM. Type I interferonopathy in a young adult. Rheumatology (Oxford). 2017;56(12):2241–3.CrossRef Manoussakis MN, Mavragani CP, Nezos A, Zampeli E, Germenis A, Moutsopoulos HM. Type I interferonopathy in a young adult. Rheumatology (Oxford). 2017;56(12):2241–3.CrossRef
16.
go back to reference Konno H, Chinn IK, Hong D, Orange JS, Lupski JR, Mendoza A, et al. Pro-inflammation associated with a gain-of-function mutation (R284S) in the innate immune sensor STING. Cell Rep. 2018;23(4):1112–23.CrossRef Konno H, Chinn IK, Hong D, Orange JS, Lupski JR, Mendoza A, et al. Pro-inflammation associated with a gain-of-function mutation (R284S) in the innate immune sensor STING. Cell Rep. 2018;23(4):1112–23.CrossRef
17.
go back to reference Saldanha RG, Balka KR, Davidson S, Wainstein BK, Wong M, Macintosh R, et al. A mutation outside the dimerization domain causing atypical STING- associated vasculopathy with onset in infancy. Front Immunol. 2018;9:1535.CrossRef Saldanha RG, Balka KR, Davidson S, Wainstein BK, Wong M, Macintosh R, et al. A mutation outside the dimerization domain causing atypical STING- associated vasculopathy with onset in infancy. Front Immunol. 2018;9:1535.CrossRef
18.
go back to reference Volpi S, Picco P, Caorsi R, Candotti F, Gattorno M. Type I interferonopathies in pediatric rheumatology. Pediatr Rheumatol Online J. 2016;14(1):35.CrossRef Volpi S, Picco P, Caorsi R, Candotti F, Gattorno M. Type I interferonopathies in pediatric rheumatology. Pediatr Rheumatol Online J. 2016;14(1):35.CrossRef
19.
go back to reference Volpi S, Tsui J, Mariani M, Pastorino C, Caorsi R, Sacco O, et al. Type I interferon pathway activation in COPA syndrome. Clin Immunol. 2018;187:33–6.CrossRef Volpi S, Tsui J, Mariani M, Pastorino C, Caorsi R, Sacco O, et al. Type I interferon pathway activation in COPA syndrome. Clin Immunol. 2018;187:33–6.CrossRef
20.
go back to reference Garcia-Romo GS, Caielli S, Vega B, et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med. 2011;3(73):73ra20.CrossRef Garcia-Romo GS, Caielli S, Vega B, et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med. 2011;3(73):73ra20.CrossRef
21.
go back to reference Frémond ML, Rodero MP, Jeremiah N, Belot A, Jeziorski E, Duffy D, et al. Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children. J Allergy Clin Immunol. 2016 Dec;138(6):1752–5.CrossRef Frémond ML, Rodero MP, Jeremiah N, Belot A, Jeziorski E, Duffy D, et al. Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children. J Allergy Clin Immunol. 2016 Dec;138(6):1752–5.CrossRef
22.
go back to reference Rodero MP, Frémond ML, Rice GI, Neven B, Crow YJ. JAK inhibition in STING-associated interferonopathy. Ann Rheum Dis. 2016;75(12):e75.CrossRef Rodero MP, Frémond ML, Rice GI, Neven B, Crow YJ. JAK inhibition in STING-associated interferonopathy. Ann Rheum Dis. 2016;75(12):e75.CrossRef
23.
go back to reference Volpi S, Insalaco A, Caorsi R, Santori E, Messia V, Sacco O, et al. Efficacy and adverse events during Janus kinase inhibitor treatment of SAVI syndrome. J Clin Immunol. 2019;39(5):476–85.CrossRef Volpi S, Insalaco A, Caorsi R, Santori E, Messia V, Sacco O, et al. Efficacy and adverse events during Janus kinase inhibitor treatment of SAVI syndrome. J Clin Immunol. 2019;39(5):476–85.CrossRef
Metadata
Title
STING-Associated Vasculopathy with Onset in Infancy in Three Children with New Clinical Aspect and Unsatisfactory Therapeutic Responses to Tofacitinib
Authors
Xiaolei Tang
Hui Xu
Chunju Zhou
Yun Peng
Hui Liu
Jinrong Liu
Huimin Li
Haiming Yang
Shunying Zhao
Publication date
01-01-2020
Publisher
Springer US
Published in
Journal of Clinical Immunology / Issue 1/2020
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-019-00690-9

Other articles of this Issue 1/2020

Journal of Clinical Immunology 1/2020 Go to the issue